ArticleFrontiers in medicine2025
Association between lipid accumulation product and non-alcoholic fatty liver disease with normal weight: a population-based study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Association of Fasting C-Peptide to High Density Lipoprotein Cholesterol Ratio with Non-Alcoholic Fatty Liver Disease in Chinese Type 2 Diabetes Mellitus Patients: A Cross-Sectional Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Previous studies have indicated that Lipid accumulation product (LAP) can serve as a predictor for various metabolic diseases. However, the relationship between LAP and Non-alcoholic fatty liver disease (NAFLD) in individuals with normal weight remains unclear. Methods: This study involves a secondary analysis of a retrospective cohort study conducted among a Japanese population consisting of 10,391 participants with normal weight, spanning from 2004 to 2015. LAP is determined by utilizing Waist circumference (WC) and Triglyceride (TG) levels. Participants were categorized into groups based on LAP quartiles. We performed an analysis of the association between LAP and NAFLD using Cox proportional-hazard regression, smooth curve fitting, and sensitivity analyses. Prediction accuracy was evaluated using the area under the curve (AUC) analysis, sensitivity, and specificity, using Receiver Operating Characteristic (ROC) curves. Results: The analysis revealed a statistically significant positive correlation between LAP and normal-weight NAFLD ( Conclusion: Our study reveals a non-linear association between the LAP and the risk of NAFLD in individuals of normal weight, with LAP demonstrating superior predictive accuracy compared to BMI and WC. These results advocate for the use of LAP thresholds to guide early lifestyle interventions during metabolically reversible stages and to improve the identification of high-risk lean individuals who may be overlooked by current BMI-based screening methods.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.